Breast cancer therapy

Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 1998 52 65-77. 

Shao, W. and Brown, M. (2004) Advances in estrogen receptor biology prospects for improvements in targeted breast cancer therapy. Breast Cancer Research, 6, 39-52. 

Human carcinoembryonic antigen Mouse/human chimeric IgGl antibody (cT84.66) Antibody - mediated cancer therapy (colon cancer, breast cancer and tumor with epithelial origin) N. tabacum cv petit Havana SRI (Transient expression) 35S MSP + 1 mg/kg FLW 42... 

Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350 1047-1059... 

Considerable synergism was found in the action of the two types of agents, both in vitro and in vivo. Figure 2.5 shows the dramatic increase of epirabicin efficacy in mice breast carcinoma in the presence of p-globin derived heptapeptide, the so called W-hemorphin-5. The data accumulated allow to consider endogenous antiproliferative peptides or their synthetic derivatives as pronusing second line pharmaceuticals for combined application with other drags in cancer therapy. 

Batist G, Barton J, Chaikin P, Swenson C, Welles L. Myocet (liposome-encapsulated doxorubicin citrate) a new approach in breast cancer therapy. Expert Opin Pharmacother 2002 3 1739-1751. 

---